Centessa Pharma jumps after Eli Lilly agrees to buy co for up to $7.8 billion

U.S.-listed shares of Centessa Pharmaceuticals CNTA.O 260y.F rise 45.9% to $40.25 premarket

Eli Lilly LLY.N to buy the Boston- and London-based drug developer for up to $7.8 billion

Upfront cash consideration represents an aggregate equity value of about $6.3 billion, with an additional ~$1.5 billion to be contingent on certain milestones, say companies

Acquisition will expand LLY's neuroscience portfolio and capabilities in sleep medicine

As of last close, CNTA up 10.3% YTD